• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Castle Biosciences (CSTL) Stock Dropped, So What Is Behind The Fresh Attention?

    Simply Wall St·11/08/2026 08:24:23
    Listen to the news

    What the raised guidance means for Castle Biosciences stock

    Castle Biosciences (CSTL) lifted its 2026 revenue outlook to US$385 million to US$395 million after strong third quarter sales and rapid TissueCypher test volume growth reshaped expectations around its diagnostics portfolio.

    Management is also pointing investors to a path toward positive adjusted EBITDA in the coming quarters and in 2027, with cash generation now a central part of the current Castle Biosciences story.

    That guidance reset landed against a choppy tape for Castle Biosciences. The share price is down 12.49% over the past week and 15.62% year to date, yet the 3 year total shareholder return of 89.29% still points to strong longer run momentum, despite a 1 year total shareholder return that is slightly lower at 1.57% and a weaker 5 year total shareholder return of 37.07%.

    Scan raised guidance stories like Castle Biosciences alongside other potential breakout candidates in our hand-picked list of 38 high quality undervalued stocks.

    Castle Biosciences now trades at a steep discount to both analyst targets and an estimated fair value, even after raised guidance and a softer share price. Is the market being prudently cautious, or is it too slow to reprice the story?

    Most Popular Narrative: 28% Undervalued

    On Simply Wall St's most followed narrative, Castle Biosciences screens as undervalued, with a fair value of $45.22 versus the last close at $32.52. This puts raised guidance against a valuation framework that leans on forecast cash flows and reimbursement outcomes.

    Castle Biosciences is expanding its test menu into underpenetrated indications such as Barrett’s esophagus and atopic dermatitis, with TissueCypher volumes rising 63% to 14,988 reports in Q2 2026 and AdvanceAD-Tx orders progressing from about 650 in Q1 2026 to more than 1,000 in Q2 2026. This points to broader exposure to new patient groups and potential support for future revenue growth.

    See why 4 investors see Castle Biosciences as 28% undervalued.

    Result: Fair Value of $45.22 (UNDERVALUED)

    Still, the Castle Biosciences narrative hinges on Medicare coverage outcomes for DecisionDx SCC and on reimbursement terms for newer assays that could pressure already softer gross margins.

    Find out about the key risks to this Castle Biosciences narrative.

    Next Steps

    Mixed signals on Castle Biosciences so far. If you feel the clock is ticking, consider both sides of the story and stress test the 2 key rewards and 1 important warning sign.

    Looking for more Castle Biosciences investment ideas?

    If Castle Biosciences has you rethinking your watchlist, broaden your search with fresh stock ideas that match different risk levels, income needs, and balance sheet preferences.